Search research articles
Contact Us
Filters
Showing results (311-320 of 487) with videos related to
Page
of 49
Sort By:
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Expert Review of Anticancer Therapy
|
December 11, 2024
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer
Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 23, 2011
Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery
Chelsea C Pinnix, Hiral P Fontanilla, Andrea Hayes-Jordan, et al.
The Oncologist
|
December 8, 2017
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
Brian A Menegaz, Branko Cuglievan, Jalen Benson, et al.
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
Cancer Chemotherapy and Pharmacology
|
October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
Salvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Molecular Cancer Therapeutics
|
February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
Page
of 49
Search research articles
Search
Showing results (311-320 of 487) with videos related to
Sort By:
Page
of 49
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Expert Review of Anticancer Therapy
|
December 11, 2024
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer
Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 23, 2011
Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery
Chelsea C Pinnix, Hiral P Fontanilla, Andrea Hayes-Jordan, et al.
The Oncologist
|
December 8, 2017
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
Brian A Menegaz, Branko Cuglievan, Jalen Benson, et al.
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
Cancer Chemotherapy and Pharmacology
|
October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
Salvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Molecular Cancer Therapeutics
|
February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
Page
of 49